Andrew James King - Aug 4, 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Role
Chief Scientific Officer
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Stock symbol
KDNY
Transactions as of
Aug 4, 2022
Transactions value $
-$98,250
Form type
4
Date filed
8/5/2022, 05:09 PM
Previous filing
Aug 2, 2022
Next filing
Oct 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDNY Common Stock Options Exercise $1.75K +5K +84.79% $0.35* 10.9K Aug 4, 2022 Direct
transaction KDNY Common Stock Sale -$100K -5K -45.88% $20.00 5.9K Aug 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Stock Option (right to buy) Options Exercise $0 -5K -8.61% $0.00 53K Aug 4, 2022 Common Stock 5K $0.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.